• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Stem Cell Exosomes Mitigate Chemotherapy Kidney Damage in Rat Preclinical Model

by
November 18, 2026
in Health
Reading Time: 6 mins read
0
Stem Cell Exosomes Mitigate Chemotherapy Kidney Damage in Rat Preclinical Model

Stem Cell Exosomes Mitigate Chemotherapy Kidney Damage in Rat Preclinical Model

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a controlled preclinical investigation evaluating experimental treatments for chemotherapy-associated renal damage, researchers demonstrated that exosomes derived from bone marrow mesenchymal stem cells substantially mitigate acute kidney injury induced by the anthracycline chemotherapeutic agent doxorubicin. The study, conducted in an in vivo rat model, revealed that systemic administration of these stem cell-derived extracellular vesicles counteracted renal structural degradation, preserved excretory organ function, and suppressed the coordinated activation of cellular oxidative stress, proinflammatory cytokine cascades, and canonical pyroptotic signaling networks. Doxorubicin continues to serve as an indispensable cornerstone of contemporary oncology for treating diverse hematologic malignancies and solid tumors, yet its clinical utility is severely hampered by off-target organ toxicities, most prominently cardiotoxicity and nephrotoxicity, for which no definitive preventative or restorative therapeutic agents currently exist. By establishing that bone marrow mesenchymal stem cell exosomes directly attenuate renal cellular injury through the modulation of a defined molecular signaling axis involving microRNA-146a-5p and key inflammasome regulators, the newly published findings provide important mechanistic insight and support the biological plausibility of vesicle-based cell-free interventions for protecting vulnerable renal tissues during intensive cytotoxic cancer regimens.

International epidemiological estimates indicate that approximately 13.3 million individuals receive a diagnosis of acute kidney injury each year, culminating in an estimated 1.7 million deaths worldwide. Etiological drivers of acute renal impairment range from systemic sepsis and traumatic rhabdomyolysis to the administration of nephrotoxic pharmacotherapy. While doxorubicin exerts potent antineoplastic effects by intercalating into cellular genomic DNA and inhibiting replication enzymes, its renal clearance generates excessive quantities of reactive oxygen species that disrupt mitochondrial membranes, damage proximal tubule epithelia, and provoke extensive cellular destruction.

Following a one-week acclimation period under standardized environmental housing conditions, the animals were randomized into four distinct experimental cohorts consisting of six animals each: a healthy control cohort, a doxorubicin-intoxicated disease cohort, a treatment cohort receiving doxorubicin followed by exosome administration, and an exosome-only safety cohort. The nephrotoxic injury regimen was established using a single intraperitoneal dose of doxorubicin administered at 15 milligrams per kilogram of body weight, a dosage calibrated through preliminary pilot dose-ranging evaluations that balanced reproducible renal damage against animal survival. Exactly twenty-four hours after the toxicological challenge, animals assigned to the treatment and vesicle-only groups received an intravenous infusion containing 100 micrograms of purified bone marrow mesenchymal stem cell-derived exosomes via systemic injection, whereas control and untreated disease cohorts received equivalent volumes of normal physiological saline. The animals were monitored under standardized care until the sixth experimental day, at which point systemic blood and bilateral kidney tissues were harvested for comprehensive histopathological, biochemical, immunohistochemical, and molecular analyses.

The biological intervention utilized in the investigation was prepared through rigorous isolation and characterization workflows aligned with the consensus guidelines established by the International Society for Extracellular Vesicles. Bone marrow mesenchymal stem cells were cultured to eighty percent confluence between the third and fifth passages, washed with phosphate-buffered saline, and maintained in extracellular vesicle-depleted media for forty-eight hours to collect secreted vesicular products. The conditioned culture supernatant underwent sequential differential centrifugation at 500 times gravity and 2,000 times gravity to clear intact cells, apoptotic bodies, and large debris, followed by intermediate centrifugation at 10,000 times gravity for twenty minutes and microfiltration across a 0.22-micrometer membrane. Vesicles were subsequently concentrated and purified via two successive rounds of high-speed ultracentrifugation at 100,000 times gravity for seventy minutes. Immunophenotypic verification via flow cytometry confirmed that the parent stem cells expressed the mesenchymal marker CD105 while lacking the hematopoietic marker CD45, and the isolated exosomes strongly displayed the canonical tetraspanin surface biomarkers CD63 and CD9 in the complete absence of CD45.

Microscopic examination of renal architecture via thin-section hematoxylin and eosin staining substantiated the profound tissue-sparing protective effects afforded by intravenous exosomal administration. Renal specimens harvested from both the healthy control cohort and the vesicle-only cohort exhibited intact structural histology, displaying well-demarcated glomeruli with normal capillary tufts, preserved Bowman space architecture, and regularly organized proximal and distal tubular epithelial boundaries without evidence of cellular damage or inflammatory infiltration. In striking contrast, renal specimens from doxorubicin-intoxicated animals demonstrated extensive histopathological destruction throughout the cortical and medullary compartments, characterized by focal glomerular necrosis, severe tubular epithelial degeneration, detachment of necrotic luminal lining cells, extensive occlusion of tubular lumens by proteinaceous and cellular casts, marked capillary retraction, and conspicuous dilation of Bowman capsule spaces accompanied by peritubular congestion, interstitial hemorrhages, and focal leukocyte infiltration. Treatment with bone marrow stem cell-derived exosomes markedly prevented these structural pathologies; tissues from the doxorubicin-plus-exosome group showed well-preserved glomerular morphology, organized capillary tufts, intact tubular basement architecture, and only minor, localized epithelial swelling and edema without significant widespread necrosis, confirming substantial histological rescue on standardized pathological scoring matrices.

Quantitative biochemical assessments of systemic circulating biomarkers and organ indices further corroborated the functional preservation of excretory renal performance following exosome delivery. In the untreated doxorubicin cohort, laboratory assays revealed severe excretory impairment, with circulating serum creatinine levels escalating by 86.18 percent and blood urea nitrogen concentrations rising by 149.23 percent relative to healthy baseline controls. Post-injury treatment with mesenchymal stem cell exosomes dramatically corrected these abnormalities, producing a 45.92 percent reduction in serum creatinine and a 70.32 percent reduction in blood urea nitrogen compared to the untreated intoxicated group, while the exosome-only control group exhibited biochemical values virtually indistinguishable from healthy animals. Furthermore, the sensitive proximal tubular necrosis biomarker kidney injury molecule-1, measured directly within renal tissue homogenates, displayed an increase of 165.18 percent following doxorubicin administration, which was significantly suppressed by 42.92 percent in animals that received subsequent exosome therapy. Pathological fluid accumulation and inflammatory hypertrophy, reflected by an elevation of 30.41 percent in the renal somatic index among doxorubicin-treated animals, were likewise significantly normalized by 18.20 percent toward healthy anatomical baselines following intravenous vesicle infusion.

Biochemical assays focused on tissue oxidation and local inflammatory cascades revealed that the renoprotective activity of the stem cell vesicles operates in part by restoring endogenous antioxidant defenses and curbing cytokine synthesis. Intoxication with doxorubicin induced profound oxidative stress within the renal parenchyma, depleting the activity of the endogenous antioxidant enzyme catalase by 51.28 percent while driving up tissue concentrations of malondialdehyde, an established secondary product of lipid peroxidation, by 141.94 percent relative to uninjured controls. Intravenous infusion of bone marrow mesenchymal stem cell exosomes effectively reversed this redox imbalance, boosting renal catalase activity by 75.61 percent and lowering tissue malondialdehyde concentrations by 35.77 percent. Concurrent evaluations of inflammatory mediators demonstrated that the chemical injury provoked an intense localized immunological reaction, elevating renal tissue levels of the key proinflammatory cytokines interleukin-1 beta and interleukin-18 by 162.65 percent and 116.81 percent, respectively. Treatment with the stem cell-derived vesicles significantly dampened this cytokine surge, reducing tissue concentrations of interleukin-1 beta by 30.25 percent and interleukin-18 by 35.18 percent, whereas administration of exosomes alone to healthy rats produced no detectable alterations in baseline oxidative or cytokine parameters.

Beyond general anti-inflammatory and antioxidant actions, the research established that exosomal administration robustly suppresses renal pyroptosis, an intensely inflammatory form of programmed cell death mediated by pore-forming executioner proteins. Immunohistochemical staining demonstrated extensive upregulation and widened reaction area percentages for both the upstream sensory scaffold NLRP3 and its downstream effector protease caspase-1 within the renal tissue of doxorubicin-exposed animals. Quantitative enzyme-linked immunosorbent assays revealed that renal tissue levels of gasdermin-D, the primary executioner protein that oligomerizes to form lytic transmembrane pores following proteolytic cleavage, surged by 295.77 percent in the diseased group compared to healthy controls. Following therapeutic exosome delivery, tissue immunoreactivity for both NLRP3 and caspase-1 dropped precipitously, accompanied by a 64.45 percent decrease in total renal gasdermin-D protein concentrations. Because canonical pyroptosis involves assembly of the NLRP3 inflammasome, subsequent autocatalytic activation of pro-caspase-1, proteolytic processing of gasdermin-D to form plasma membrane channels, and the violent extracellular release of mature interleukin-1 beta and interleukin-18, the coordinated suppression of these markers confirms that exosome therapy arrests this destructive lytic cascade in poisoned tubular cells.

To unravel the precise regulatory mechanisms governing this therapeutic response, the investigators integrated molecular expression profiling with comprehensive in silico bioinformatic network modeling. Exosomal treatment reversed this pathological signature, driving a 728.77 percent surge in relative microRNA-146a-5p abundance, decreasing IRAK1 messenger RNA and protein levels by 48.39 percent and 51.80 percent, decreasing ELAVL1 messenger RNA and protein levels by 48.39 percent and 29.38 percent, and lowering nuclear factor NF-kappaB protein content by 50.84 percent. Bioinformatic interrogations across RNA22 databases predicted stable, energetically favorable binding conformations between microRNA-146a-5p and the transcripts of both IRAK1 and ELAVL1, while STRING interactome networks and ENCORI CLIP-sequencing databases identified extensive physical binding connections linking ELAVL1 directly to the transcripts of NF-kappaB, NLRP3, and interleukin-18, outlining a biologically cohesive regulatory axis whereby exosome-delivered microRNA inhibits inflammatory kinase and RNA-binding cascades to block inflammasome activation.

The study highlights important translational advantages associated with exosomal formulations while delineating key experimental boundaries that require future laboratory exploration. Compared to living mesenchymal stem cell transplantation, cell-free exosome therapy circumvents critical clinical liabilities, including risks of unregulated cellular differentiation, potential tumorigenicity, host immunological rejection, and pulmonary microembolism following systemic vascular infusion, while offering enhanced biophysical stability during storage and standardized pharmacological dosing. Nevertheless, the investigators acknowledged explicit limitations inherent to their experimental methodology, noting that caspase-1 and gasdermin-D were quantified as total cellular protein expression rather than cleavage-specific proteolytic fragments or functional membrane-pore assays, meaning these measurements reflect broader inflammasome signaling rather than isolated cell-death execution. Furthermore, the bioinformatically predicted binding between microRNA-146a-5p and its downstream targets requires direct confirmation via dual-luciferase reporter assays and targeted genetic gain-and-loss-of-function studies, and formal in vivo organ tracking is needed to map vesicle biodistribution kinetics in living subjects. Continued mechanistic validation and formulation optimization will be essential to establish whether these preclinical observations can successfully transition into viable clinical strategies for safeguarding human kidney function during chemotherapy.

Subject of Research: Bone marrow stem cell exosomes mitigating doxorubicin nephrotoxicity

Article Title: Bone marrow mesenchymal stem cells-derived exosomes ameliorate doxorubicin-induced nephrotoxicity via the modulation of pyroptosis-associated signaling

Article References: Shahin, R. K., Elazazy, O., Wahdan, S. A., & AbdelHamid, S. G. (2026). Bone marrow mesenchymal stem cells-derived exosomes ameliorate doxorubicin-induced nephrotoxicity via the modulation of pyroptosis-associated signaling. Molecular Medicine, 32(1), Article 199. https://doi.org/10.1186/s10020-026-01655-6

Image Credits: AI Generated

DOI: 10.1186/s10020-026-01655-6

Keywords: acute kidney injury, doxorubicin, nephrotoxicity, mesenchymal stem cells, exosomes, pyroptosis, NLRP3 inflammasome, miR-146a-5p, caspase-1, gasdermin-D, ELAVL1, IRAK1, NF-kappaB, oxidative stress, catalase, malondialdehyde, biomarkers, preclinical nephrology

News Source: Drew Townsend. (November 18, 2026). Stem Cell Exosomes Mitigate Chemotherapy Kidney Damage in Rat Preclinical Model. Scienmag.

Tags: acute kidney injurybiomarkerscaspase-1catalasedoxorubicinELAVL1ExosomesGasdermin DIRAK1malondialdehydemesenchymal stem cellsmiR-146a-5pNephrotoxicityNF-kappaBNLRP3 inflammasomeoxidative stresspreclinical nephrologypyroptosis
Share12Tweet7Share2ShareShareShare1

Related Posts

SARS-CoV-2 Antibodies Detected in European Moose and Asian Golden Cat

SARS-CoV-2 Antibodies Detected in European Moose and Asian Golden Cat

November 18, 2026
Topical Eye Treatments Linked to Corneal Structural Differences in Congenital Aniridia

Topical Eye Treatments Linked to Corneal Structural Differences in Congenital Aniridia

November 18, 2026

Dapagliflozin and Aerobic Exercise Reduce Hepatic Steatosis in Diabetic Rats

November 18, 2026

Adaptive Brain Stimulation Shows Motor Improvement in Parkinson’s Review Amid Heterogeneity

November 18, 2026

POPULAR NEWS

  • Streaming Framework With Hybrid Machine Learning Achieves Sub-Forty-Millisecond Intrusion Detection

    Streaming Framework With Hybrid Machine Learning Achieves Sub-Forty-Millisecond Intrusion Detection

    29 shares
    Share 12 Tweet 7
  • Multidisciplinary Protocol Aids Mitral Valve Repair in Post-Infarction Shock Case

    29 shares
    Share 12 Tweet 7
  • Physical Exercise Linked to Lower Relative Health Disadvantage Among Older Adults

    29 shares
    Share 12 Tweet 7
  • Adolescent Brain Connectivity Predicts Depression and Anxiety Trajectories Over 18 Months

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

SARS-CoV-2 Antibodies Detected in European Moose and Asian Golden Cat

Feedback Loop Between Two Transcription Factors Drives Apple Aroma During Ripening

Topical Eye Treatments Linked to Corneal Structural Differences in Congenital Aniridia

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.